Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

E. Resta (Foggia, Italy), G. Carpagnano (Bari, Italy), C. Pelaia (Catanzaro, Italy), M. D'Amato (Napoli, Italy), N. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), C. Calabrese (Napoli, Italy), O. Resta (Bari, Italy), G. Scioscia (Foggia, Italy), G. Pelaia (Catanzaro, Italy), M. Foschino Barbaro (Foggia, Italy)

Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Session: How do different treatment strategies translate into costs
Session type: Oral Presentation
Number: 4809

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Resta (Foggia, Italy), G. Carpagnano (Bari, Italy), C. Pelaia (Catanzaro, Italy), M. D'Amato (Napoli, Italy), N. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), C. Calabrese (Napoli, Italy), O. Resta (Bari, Italy), G. Scioscia (Foggia, Italy), G. Pelaia (Catanzaro, Italy), M. Foschino Barbaro (Foggia, Italy). Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. 4809

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: